InVivo Therapeutics

InVivo Therapeutics

InVivo Therapeutics

InVivo Therapeutics (NASDAQ:NVIV) is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.
Founded
2005
Raised
$45.2M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$32,200,000
Post-IPO equity - 2016
$13,000,000
Venture capital - 2010
Spencer Trask
Team Size
10+
Employees
$32,200,000 Post-IPO equity
MassDevice

InVivo raises $32m, enrolls 7th patient in Inspire study